Trial reportBMC oral health2026
Clinical effectiveness of theobromine, Remin Pro, and their combination in managing dentin hypersensitivity: a randomized clinical trial.
Trial report in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04340869 (The Effect of Using Two Desensitizing Agents Alone and In Combination on Dentin Permeability and Hypersensitivity), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Using Two Desensitizing Agents Alone and In Combination on Dentin Permeability and Hypersensitivity
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDentin hypersensitivity is a prevalent and debilitating condition affecting 10-30% of the adult population worldwide, yet the comparative short-term clinical effectiveness of emerging natural and remineralizing desensitizing agents remains incompletely characterized. This study evaluated and compared the clinical effectiveness of theobromine gel, a hydroxyapatite-fluoride-xylitol remineralizing paste (Remin Pro), and their combination in the management of dentin hypersensitivity.
methodsA single-center, double-blind, randomized clinical study was conducted in 171 teeth from 20 patients with confirmed dentin hypersensitivity, randomly allocated to three equal groups (n = 57 per group) receiving either theobromine gel, a hydroxyapatite-fluoride-xylitol remineralizing paste (Remin Pro), or their combination. Three applications were administered sequentially at baseline, one week, and one month. Pain intensity in response to tactile, evaporative, and cold-thermal stimuli was assessed at four time points: before treatment, immediately after the first application, after the second application at one week, and after the third application at one month, using the Verbal Rating Scale and Visual Analogue Scale. Data were analyzed using nonparametric tests and are reported as median and interquartile range.
resultsAll three treatment modalities produced a statistically significant, progressive reduction in dentin hypersensitivity over time. Theobromine demonstrated significantly greater pain reduction than Remin Pro after the first and second applications, most consistently in response to evaporative and cold-thermal stimuli. After the third application, all three groups achieved broadly comparable pain reduction, with no statistically significant differences in tactile stimulation or overall pain scores.
conclusionsWithin the limitations of this short-term study, Theobromine gel provides clinically faster desensitization than a hydroxyapatite-fluoride-xylitol remineralizing paste after initial applications, a distinction of practical relevance for patients requiring prompt pain relief. After three sequential applications, all agents achieve comparable clinical effectiveness, confirming that multi-application protocols are the standard of care regardless of agent selection. These findings support the use of theobromine as a viable, biocompatible alternative for the short-term management of dentin hypersensitivity and justify further investigation in long-term, placebo-controlled randomized trials.
trial registrationClinicalTrials.gov, NCT04340869. Registered March 2, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.